RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA MARKET ANALYSIS

Regional Analysis

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Regional Analysis

• Among regions, North America is estimated to hold a dominant position in the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. North America is estimated to hold 39.1% of the market share in 2023. The market is expected to witness significant growth in the near futuresdue to high incidence rate of r/r DLBCL. In 2021, the incidence rate of NHL in the U.S  was estimated at 19.6 cases per 100,000 per year. In 2020, an estimated 73,652 new NHL cases were reported in the U.S For DLBCL specifically, the estimated incidence rate is 4.68 cases per 100,000 per year in the U.S.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Regional Analysis

• Among regions, North America is estimated to hold a dominant position in the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. North America is estimated to hold 39.1% of the market share in 2023. The market is expected to witness significant growth in the near future due to the high incidence rate of r/r DLBCL. In 2021, the incidence rate of NHL in the U.S was estimated at 19.6 cases per 100,000 per year. In 2020, an estimated 73,652 new NHL cases were reported in the US. For DLBCL specifically, the estimated incidence rate is 4.68 cases per 100,000 per year in the US.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Cross Sectional Analysis:

Key players are making relapsed or refractory diffuse large B cell lymphoma with combination of drug which is expected to drive the relapsed or refractory diffuse large B cell lymphoma market in North America region. For instance, in April 2021, Eagle Pharmaceuticals, Inc., a pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2) liquid formulation had  been approved for a new indication in combination with rituximab (“BR therapy”) as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”) by the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan.